CenterBook Partners LP decreased its position in shares of Clarivate PLC (NYSE:CLVT - Free Report) by 49.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 703,574 shares of the company's stock after selling 687,134 shares during the period. CenterBook Partners LP owned approximately 0.10% of Clarivate worth $2,765,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. AustralianSuper Pty Ltd purchased a new position in shares of Clarivate during the first quarter valued at $39,593,000. Price T Rowe Associates Inc. MD increased its position in shares of Clarivate by 53.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,776,892 shares of the company's stock worth $141,107,000 after purchasing an additional 9,691,104 shares in the last quarter. Norges Bank purchased a new stake in Clarivate in the fourth quarter valued at about $27,764,000. Clarkston Capital Partners LLC boosted its stake in Clarivate by 8.1% in the 4th quarter. Clarkston Capital Partners LLC now owns 70,733,831 shares of the company's stock worth $359,328,000 after purchasing an additional 5,319,535 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Clarivate during the fourth quarter valued at $19,172,000. Institutional investors own 85.72% of the company's stock.
Insider Activity
In other news, insider James Gordon Samson sold 100,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $4.53, for a total value of $453,000.00. Following the transaction, the insider directly owned 1,271,103 shares of the company's stock, valued at approximately $5,758,096.59. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 23.18% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Separately, Wall Street Zen lowered shares of Clarivate from a "buy" rating to a "hold" rating in a research note on Saturday, June 21st.
View Our Latest Stock Analysis on CLVT
Clarivate Price Performance
Shares of CLVT stock traded up $0.14 during mid-day trading on Thursday, hitting $4.32. 2,933,435 shares of the stock were exchanged, compared to its average volume of 5,795,369. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.90. Clarivate PLC has a 52-week low of $3.04 and a 52-week high of $7.15. The firm has a fifty day moving average of $4.30 and a 200 day moving average of $4.38. The company has a market cap of $2.95 billion, a PE ratio of -4.45 and a beta of 1.47.
Clarivate (NYSE:CLVT - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. The business had revenue of $593.70 million during the quarter, compared to analysts' expectations of $574.03 million. Clarivate had a negative net margin of 26.32% and a positive return on equity of 8.75%. The company's quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share. Research analysts anticipate that Clarivate PLC will post 0.63 earnings per share for the current year.
About Clarivate
(
Free Report)
Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications.
Featured Articles
Before you consider Clarivate, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clarivate wasn't on the list.
While Clarivate currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
